These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32067270)

  • 1. ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.
    Gose T; Shafi T; Fukuda Y; Das S; Wang Y; Allcock A; Gavan McHarg A; Lynch J; Chen T; Tamai I; Shelat A; Ford RC; Schuetz JD
    FASEB J; 2020 Apr; 34(4):4890-4903. PubMed ID: 32067270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2.
    Kowal J; Ni D; Jackson SM; Manolaridis I; Stahlberg H; Locher KP
    J Mol Biol; 2021 Jun; 433(13):166980. PubMed ID: 33838147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 transports anticancer drugs via a closed-to-open switch.
    Orlando BJ; Liao M
    Nat Commun; 2020 May; 11(1):2264. PubMed ID: 32385283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.
    Manolaridis I; Jackson SM; Taylor NMI; Kowal J; Stahlberg H; Locher KP
    Nature; 2018 Nov; 563(7731):426-430. PubMed ID: 30405239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
    Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
    Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
    Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
    Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
    Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
    Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
    Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2.
    Jackson SM; Manolaridis I; Kowal J; Zechner M; Taylor NMI; Bause M; Bauer S; Bartholomaeus R; Bernhardt G; Koenig B; Buschauer A; Stahlberg H; Altmann KH; Locher KP
    Nat Struct Mol Biol; 2018 Apr; 25(4):333-340. PubMed ID: 29610494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach.
    Le MT; Hoang VN; Nguyen DN; Bui TH; Phan TV; Huynh PN; Tran TD; Thai KM
    Molecules; 2021 May; 26(11):. PubMed ID: 34071039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
    Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
    Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
    Beebe J; Zhang JT
    J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.